Chemistry (relationship)

PointsBet Unveils New NFL Live Betting Feature "Lightning Bets," Leading to Record Number of Live Bets During NFL Week 5

Retrieved on: 
Wednesday, October 12, 2022
Congress, Banach, MLB, ADW, Association, Chemistry (relationship), Gambling, Cincinnati Bengals, Lightning, Research, Susquehanna International Group, NFL, World, NBA, Partnership, Australian Securities Exchange, Sunday Night Football, Sport, Las Vegas Raiders, Acquisition, NBA playoffs, Line (geometry), Hunger, SIG, Straight Lines (song), Algorithm, Online gambling

DENVER, Oct. 12, 2022 /PRNewswire/ -- PointsBet, the home of live betting, today announced it has successfully enabled a homepage feature of NFL Lightning Bets on the PointsBet app, leading to a 108% increase in Lightning Bets handle and 184% increase in unique customers using the product week over week. During week 5 of Sunday Night Football, NFL Lightning Bets were the most popular live markets and third highest in terms of handle. This development comes on the heels of PointsBet announcing its upcoming integration of in-app content, featuring clips from PointsBet-produced shows such as The Straight Line with Ryan Leaf, to further build out its live betting functionality.

Key Points: 
  • During week 5 of Sunday Night Football, NFL Lightning Bets were the most popular live markets and third highest in terms of handle.
  • Placing an emphasis on live betting has become a key objective for PointsBet in its mission to disrupt the sports betting status quo in the North American market.
  • "Live, in-game betting is not only the future of the American sports market, but it's what the sports bettor wants right now.
  • Banach, an Ireland-based software company that creates sports betting platforms and algorithms, has been critical in enhancing PointsBet's live betting offerings.

EQS-News: DEFENCE THERAPEUTICS INITIATES LUNG CANCER TREATMENT PROGRAM WITH ITS NOVEL ACCUTOXTM FORMULATION VIA INTRANASAL

Retrieved on: 
Wednesday, October 12, 2022
Therapy, Hand, DNA repair, Vaccine, CAGR, Neoplasm, DNA replication, Research, Malignancy, Cell, Technology, Cancer, Infection, Chemistry (relationship), Lung cancer, Company, Cell death, CSE, CEO, ADC, Small-cell carcinoma, News, Genome, Defense, Forward-looking statement, DNA, Cell division, Catastrophic illness, USD, Carcinoid syndrome, Engineering, Control, Large-cell lung carcinoma, Security (finance), BC

The novel AccuTOXTM formulation is designed for the treatment of lung cancer including various types of malignancy of the upper or lower respiratory tracks.

Key Points: 
  • The novel AccuTOXTM formulation is designed for the treatment of lung cancer including various types of malignancy of the upper or lower respiratory tracks.
  • The AccuTOXTM will be delivered intranasal to effectively deliver the AccuTOXTM into the transmucosal and will target the lungs.
  • The AccuTOXTM technology is an AccumTM variant developed by Defence Therapeutics to specifically halt tumor growth when administered intratumorally.
  • Small cell lung cancer, lung carcinoid tumor and non-small cell lung cancer are three different types of lung cancer.

Mikart and Nano PharmaSolutions have entered into a collaboration agreement to manufacture clinical trial materials using NanoTransformer™ Technology

Retrieved on: 
Tuesday, October 11, 2022
SAN, LinkedIn, API, Polymer, GMP, LLC, Chemistry (relationship), Solubility, Drug development, Business, Multimedia, PVD, Technology, Doctor of Philosophy, CDMO, PhD-MBA, NPS, Environment, Nanotechnology, Nanoparticle, Solvent, Nanomedicine, Fine chemical

This differentiated, solvent-free, nano-granulation process for drug development and manufacturing provides our customers with an alternative solubility enhancement technology."

Key Points: 
  • This differentiated, solvent-free, nano-granulation process for drug development and manufacturing provides our customers with an alternative solubility enhancement technology."
  • Kay Olmstead, PhD/MBA, Chief Executive Officer at NPS, added, "Nano PharmaSolutions is excited for this collaboration which will provide us with GMP manufacturing capabilities for development of nanomedicines, using our NanoTransformer technology at Mikart's facility."
  • Louis Weber, Vice President of Business Development at Mikart, added, "Mikart is committed to offering innovative options for enhancing solubility and bioavailability to our customers.
  • Nano PharmaSolutions, Inc. developed a NanoTransformer technology that generates nanoparticles of active pharmaceutical ingredients with physical vapor deposition (PVD), a nanocoating method without using any polymers or solvents.

Colibrí™, COPAN's Automated Specimen Workup Instrument, Receives FDA 510(k) Clearance for use with bioMérieux VITEK® 2 Antimicrobial Susceptibility Testing (AST) System

Retrieved on: 
Monday, October 10, 2022
Pressure, AST, WASP, MS, TAG, Attention, Laboratory, Workflow, Algorithm, Chemistry (relationship), Seed, Entrepreneurship, Multimedia, Collection, Artificial intelligence, Tagi of Ginti, Automation, Company, CEO, McFarland, Robotics, Heart, FDA, ID, Solution, Complex, View, MALDI, Medical device, Microbiology

This new Colibr 510(k) clearance announcement is exciting because it substantiates that fully automated culture workup for ID and AST is possible.

Key Points: 
  • This new Colibr 510(k) clearance announcement is exciting because it substantiates that fully automated culture workup for ID and AST is possible.
  • "Clinical microbiology is facing tremendous challenges, including labor shortages, dramatically increased workloads, pressure for on-demand testing, and rapid turnaround times for results.
  • The FDA clearance of COPAN's Colibr for MALDI and now Vitek 2 will save time and labor by automating crucial steps in diagnostic microbiology.
  • The system is now FDA cleared for the preparation of microbial suspensions for AST with bioMrieux VITEK 2.

Veladero, Barrick’s joint venture in Argentina, continues to explore and strengthen its partnership with the community

Retrieved on: 
Friday, October 7, 2022
SAN, CDC, Insurance, Communication, Risk, SEC, Terrorism, Loss, Transport, Pandemic, Electricity, Natural gas, Corruption, Chemistry (relationship), Bristow, Perception, COVID-19, Investment, Partnership, Goal, Company, Silver, Accident, Industry, Health, Water, Intention, Copper, Tax, Epidemic, Gold, GLOBE, Climate change, Maintenance, Forward-looking statement, DNA, Nationalization, Failure, Weather, Engineering, Mining, Risk management, Veladero

We call San Juan our home and since 2019 we have significantly improved our relations with all stakeholders based on our DNA of open and transparent communication.

Key Points: 
  • We call San Juan our home and since 2019 we have significantly improved our relations with all stakeholders based on our DNA of open and transparent communication.
  • Im thrilled to see this commitment expand with the installation of new Community Development Committees in our neighboring communities of Iglesia and Jchal, Bristow said.
  • Over the next six months, monitoring will occur monthly and then quarterly, significantly increasing participation from the current annual frequency.
  • All of the forward-looking statements made in this press release are qualified by these cautionary statements.

Enforcement Notice - Decision - 22-0158 - IIROC Sanctions Neil DiCostanzo

Retrieved on: 
Thursday, October 6, 2022
Conduct, Chemistry (relationship), Investment Industry Regulatory Organization of Canada, Coup d'État: A Practical Handbook, Enforcement, Record, Investment, Foster, Financial adviser, Property management, IIROC

The decision on Liability can be found at:

Key Points: 
  • The decision on Liability can be found at:
    IIROC formally initiated the investigation into Mr. DiCostanzo's conduct in May 2018.
  • All information about disciplinary proceedings relating to current and former member firms is available in the Enforcement section of the IIROC website.
  • IIROC is the pan-Canadian self-regulatory organization that oversees all investment dealers and their trading activity in Canada's debt and equity markets.
  • IIROC sets high quality regulatory and investment industry standards, protects investors and strengthens market integrity while supporting healthy Canadian capital markets.

CSE Bulletin: Suspensions (CBP, GNOM)

Retrieved on: 
Thursday, October 6, 2022
National instrument, Debout sur le Zinc, Chemistry (relationship), S, CSE, Politique, Policy, Online shopping

Toronto, Ontario--(Newsfile Corp. - le 6 octobre/October 2022) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - le 6 octobre/October 2022) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3.
  • The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading Rules.
  • For more information about Cease Trade Orders, visit the Canadian Securities Administrators Cease Trade Order database at www.securities-administrators.ca
    En vigueur immdiatement, les socits suivantes sont suspendues conformment la politique 3 du CSE.
  • Les suspensions sont considres comme des arrts rglementaires au sens du Rglement 23-101 sur les rgles de ngociation.

Enforcement Notice - Decision - 22-0153 - IIROC Imposes Sanctions on MD Management Limited

Retrieved on: 
Wednesday, October 5, 2022
Indian Residential Schools Settlement Agreement, Chemistry (relationship), Investment Industry Regulatory Organization of Canada, Enforcement, MD, Settlement, MDM, NL, Financial adviser, Property management, IIROC

Between 2006 and 2019, MD Management Limited did not have adequate internal controls relating to the secure management of cheques made payable to its clients contrary to IIROC Dealer Member Rules 38.1 and 2500.

Key Points: 
  • Between 2006 and 2019, MD Management Limited did not have adequate internal controls relating to the secure management of cheques made payable to its clients contrary to IIROC Dealer Member Rules 38.1 and 2500.
  • Pursuant to the Settlement Agreement, MD Management Limited agreed to the following penalty:
    Payment of a fine in the sum of $200,000.
  • MD Management Limited also agreed to pay costs in the amount of $25,000.
  • The Settlement Agreement is available at:
    IIROC formally initiated the investigation into MD Management Limited conduct in December 2019.

Cell Health Company MitoQ Sets Out to Boost Arterial and Heart Health

Retrieved on: 
Monday, October 3, 2022
Energy level, Heart, Chemistry (relationship), Technology, Research, Clinical trial, Vegetable, University of Colorado Boulder, CEO, Health, Coenzyme Q10, Antioxidant, Immune system, Cell, Fruit, Mitochondrion, University, Artery, Senior, Pharmaceutical industry, Dietary supplement

Auckland, New Zealand--(Newsfile Corp. - October 3, 2022) - Cell and mitochondrial health firm, MitoQ , has announced that it is seeking to further support research into heart health through its targeted cell health molecule, which is available in a range of supplements.

Key Points: 
  • Auckland, New Zealand--(Newsfile Corp. - October 3, 2022) - Cell and mitochondrial health firm, MitoQ , has announced that it is seeking to further support research into heart health through its targeted cell health molecule, which is available in a range of supplements.
  • Through its pioneering, one-of-a-kind technology, MitoQ is hoping to provide a new way of supporting cardiovascular health, particularly as people age.
  • As a result, alongside the heart health benefits, MitoQ also enhances daily energy-levels, supports the immune system and reduces the speed of cell aging .
  • For instance, we are excited about the research that has confirmed the role of MitoQ in helping heart health.

AeroRx Partners with HCmed to Develop a Nebulized LABA/LAMA Combination Solution for the Treatment of Chronic Obstructive Pulmonary Disease

Retrieved on: 
Monday, October 3, 2022
Solution, Chronic obstructive pulmonary disease, Technology, CEO, CDRO, Chemistry (relationship), Partnership, LLC, Therapy, Quality of life, LABA, Asthma, Patient, COPD, Organization, Population, Pharmaceutical industry

(AeroRx) and HCmed Innovations Co., Ltd. (HCmed) have initiated a collaboration, introducing a LABA/LAMA combination solution for delivery with a breath-actuated nebulizer.

Key Points: 
  • (AeroRx) and HCmed Innovations Co., Ltd. (HCmed) have initiated a collaboration, introducing a LABA/LAMA combination solution for delivery with a breath-actuated nebulizer.
  • This collaboration sets forth the framework by which both companies will work together to develop a new nebulized combination formulation for the treatment of chronic obstructive pulmonary disease (COPD).
  • AeroRx is currently developing the first nebulized LABA/LAMA combination solution, which could benefit 7-19% of the COPD population.
  • Jason Cheng, CEO and founder of HCmed, mentioned, "We are excited to announce our partnership with AeroRx.